scorecardresearch
Follow Us:
Sunday, October 24, 2021

Glenmark Pharmaceuticals

GLENMARK PHARMACEUTICALS NEWS

Study finds no new safety signals with use of Favipiravir, side effects mild

September 16, 2021 8:24 am

A statement issued Wednesday said the PMS study commenced in July 2020 to evaluate the safety and efficacy of Favipiravir in mild to moderate Covid-19 patients.

Glenmark Life Sciences shares list with over 4% gain

August 06, 2021 1:30 pm

Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals, is a leading developer and manufacturer of select high-value, non-commoditised Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas.

Glenmark Life Sciences IPO share allotment status: Here’s how to check your shares

August 03, 2021 9:28 pm

Glenmark Life Sciences IPO allotment status: Initial public offering (IPO) of Glenmark Life Sciences, the wholly-owned subsidiary of Glenmark Pharmaceuticals, was subscribed 44.17 times and the shares will now get allotted to investors. Here's how to check if you have been allotted the shares.

IPO Wrap: Glenmark Life Sciences IPO subscribed 44.17 times on final day led by non institutional investors, QIBs

July 30, 2021 9:45 am

Glenmark Life Sciences IPO subscription status: Glenmark Life Sciences IPO was subscribed 44.17 times on the final day of the offer.

Glenmark Pharmaceuticals shares tumble nearly 6%

July 20, 2020 1:23 pm

Glenmark Pharmaceuticals stock declined 5.10 per cent to Rs 408 on the BSE and at the NSE, it tanked 5.75 per cent to Rs 405.

Chandigarh residents demand fabi-flu, chemists struggle to explain it’s not a ‘cure’ for coronavirus

June 26, 2020 10:39 am

The Indian Express spoke to 20 chemist store owners across the city, most of whom insisted that customers need a prescription and have to sign a form consenting to consume the medicine before they are allowed to purchase the drug from chemists.

Glenmark Pharmaceuticals shares soar 20 per cent after COVID-19 drug launch

June 22, 2020 1:25 pm

The scrip jumped 19.99 per cent to Rs 490.90 -- its upper circuit limit -- on the BSE. On the NSE, it zoomed 19.99 per cent to Rs 491.20 -- its highest permissible trading limit for the day.

Glenmark to market the antiviral under the brand name 'FabiFlu'

June 22, 2020 12:57 pm

Favipiravir is backed by strong clinical evidence showing encouraging results in patients with mild to moderate COVID-19.

Glenmark Pharma gets DCGI nod for clinical trials of Favipiravir tablets on COVID-19 patients

April 30, 2020 2:03 pm

The Mumbai-based company is the first pharmaceutical company in India to be given an approval by the regulator to start the trial on COVID-19 patients in the country.

Glenmark Pharma shares jump nearly 9% on DCGI nod for clinical trials of COVID-19 tablets

April 30, 2020 1:26 pm

The scrip jumped 8.88 per cent to Rs 359 on the BSE. On the NSE, it zoomed 8.88 per cent to Rs 359.